We evaluated the levels of AKR1B1 and AKR1B10 in 99 patients with high-grade serous ovarian cancer and their association with clinicopathological characteristics, survival, and response to chemotherapy. This evidence concerns the gene AKR1B10 and ovarian serous adenocarcinoma.